A detailed history of Qube Research & Technologies LTD transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 64,683 shares of TARS stock, worth $3.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,683
Previous 226,879 71.49%
Holding current value
$3.35 Million
Previous $6.17 Million 65.5%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.54 - $34.6 $3.49 Million - $5.61 Million
-162,196 Reduced 71.49%
64,683 $2.13 Million
Q2 2024

Aug 14, 2024

BUY
$25.17 - $38.73 $4.87 Million - $7.49 Million
193,516 Added 580.03%
226,879 $6.17 Million
Q1 2024

May 14, 2024

BUY
$19.61 - $39.22 $539,961 - $1.08 Million
27,535 Added 472.46%
33,363 $1.21 Million
Q4 2023

Feb 13, 2024

BUY
$12.98 - $20.73 $75,647 - $120,814
5,828 New
5,828 $118,000
Q1 2023

May 15, 2023

BUY
$11.92 - $16.27 $123,395 - $168,427
10,352 New
10,352 $130,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.38B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.